159 related articles for article (PubMed ID: 35024313)
1. Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity.
Jilek JL; Frost KL; Jacobus KA; He W; Toth EL; Goedken M; Cherrington NJ
Acta Pharm Sin B; 2021 Dec; 11(12):3869-3878. PubMed ID: 35024313
[TBL] [Abstract][Full Text] [Related]
2. Representative Rodent Models for Renal Transporter Alterations in Human Nonalcoholic Steatohepatitis.
Frost KL; Jilek JL; Toth EL; Goedken MJ; Wright SH; Cherrington NJ
Drug Metab Dispos; 2023 Aug; 51(8):970-981. PubMed ID: 37137719
[TBL] [Abstract][Full Text] [Related]
3. Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.
Jilek JL; Frost KL; Marie S; Myers CM; Goedken M; Wright SH; Cherrington NJ
Drug Metab Dispos; 2022 Oct; 50(10):1389-1395. PubMed ID: 34921099
[TBL] [Abstract][Full Text] [Related]
4. Gene-by-Environment Interaction of Bcrp
Toth EL; Li H; Dzierlenga AL; Clarke JD; Vildhede A; Goedken M; Cherrington NJ
Drug Metab Dispos; 2018 Nov; 46(11):1478-1486. PubMed ID: 30166404
[TBL] [Abstract][Full Text] [Related]
5. Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.
Laho T; Clarke JD; Dzierlenga AL; Li H; Klein DM; Goedken M; Micuda S; Cherrington NJ
Biochem Pharmacol; 2016 Sep; 115():144-51. PubMed ID: 27381944
[TBL] [Abstract][Full Text] [Related]
6. Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.
Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Goedken MJ; Cherrington NJ
Drug Metab Dispos; 2015 Feb; 43(2):266-72. PubMed ID: 25488932
[TBL] [Abstract][Full Text] [Related]
7. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events.
Iwata K; Aizawa K; Kamitsu S; Jingami S; Fukunaga E; Yoshida M; Yoshimura M; Hamada A; Saito H
Clin Exp Nephrol; 2012 Dec; 16(6):843-51. PubMed ID: 22569819
[TBL] [Abstract][Full Text] [Related]
8. Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.
Clarke JD; Hardwick RN; Lake AD; Canet MJ; Cherrington NJ
J Pharmacol Exp Ther; 2014 Mar; 348(3):452-8. PubMed ID: 24403518
[TBL] [Abstract][Full Text] [Related]
9. Interaction of Oatp1b2 expression and nonalcoholic steatohepatitis on pravastatin plasma clearance.
Toth EL; Clarke JD; Csanaky IL; Cherrington NJ
Biochem Pharmacol; 2020 Apr; 174():113780. PubMed ID: 31881192
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant effect of ascorbic acid against cisplatin-induced nephrotoxicity and P-glycoprotein expression in rats.
Okamoto K; Kitaichi F; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Eur J Pharmacol; 2021 Oct; 909():174395. PubMed ID: 34332922
[TBL] [Abstract][Full Text] [Related]
11. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.
Canet MJ; Hardwick RN; Lake AD; Dzierlenga AL; Clarke JD; Cherrington NJ
Drug Metab Dispos; 2014 Apr; 42(4):586-95. PubMed ID: 24384915
[TBL] [Abstract][Full Text] [Related]
12. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.
Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ
Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715
[TBL] [Abstract][Full Text] [Related]
14. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.
Yokoo K; Murakami R; Matsuzaki T; Yoshitome K; Hamada A; Saito H
Clin Exp Nephrol; 2009 Dec; 13(6):578-84. PubMed ID: 19629622
[TBL] [Abstract][Full Text] [Related]
15. A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.
Montonye ML; Tian DD; Arman T; Lynch KD; Hagenbuch B; Paine MF; Clarke JD
J Pharmacol Exp Ther; 2019 Nov; 371(2):385-393. PubMed ID: 31420525
[TBL] [Abstract][Full Text] [Related]
16. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease.
Lickteig AJ; Fisher CD; Augustine LM; Aleksunes LM; Besselsen DG; Slitt AL; Manautou JE; Cherrington NJ
Drug Metab Dispos; 2007 Oct; 35(10):1970-8. PubMed ID: 17640958
[TBL] [Abstract][Full Text] [Related]
17. Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination.
Frost KL; Jilek JL; Sinari S; Klein RR; Billheimer D; Wright SH; Cherrington NJ
Drug Metab Dispos; 2023 Feb; 51(2):155-164. PubMed ID: 36328481
[TBL] [Abstract][Full Text] [Related]
18. Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III.
Chatterjee S; Mukherjee S; Sankara Sivaprasad LVJ; Naik T; Gautam SS; Murali BV; Hadambar AA; Gunti GR; Kuchibhotla V; Deyati A; Basavanthappa S; Ramarao M; Mariappan TT; Zinker BA; Zhang Y; Sinz M; Shen H
J Pharmacol Exp Ther; 2021 Jan; 376(1):29-39. PubMed ID: 33127749
[TBL] [Abstract][Full Text] [Related]
19. Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate.
Ali I; Slizgi JR; Kaullen JD; Ivanovic M; Niemi M; Stewart PW; Barritt AS; Brouwer KLR
Clin Pharmacol Ther; 2017 Dec; ():. PubMed ID: 29271075
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Proteomics and Mechanistic Modeling of Transporter-Mediated Disposition in Nonalcoholic Fatty Liver Disease.
Vildhede A; Kimoto E; Pelis RM; Rodrigues AD; Varma MVS
Clin Pharmacol Ther; 2020 May; 107(5):1128-1137. PubMed ID: 31630405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
